BMYCelgeneFinished
A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers
Neoplasms
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2
- Patients
- 92 (final count)
- Started
- Jul 14, 2020
- Main results expected
- Dec 19, 2023
- Fully finished
- Dec 19, 2023
- Results posted
- Jan 22, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate
Measured over: Every 6 weeks post Cycle 1 (each cycle is of 28 days) Day 1 for the first 24 weeks and then every 8 weeks until disease progression, new anticancer therapy, death or withdrawal by participants (up to approximately 33 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04350463 · record last updated 2025-01-22 · checked 2026-11-09 15:47 UTC